Research programme: kinase modulators - Blueprint Medicines

Drug Profile

Research programme: kinase modulators - Blueprint Medicines

Alternative Names: BLU 6864; BLU 9931; BLU-667; c-KIT D816V inhibitor - Blueprint Medicines; Fibroblast growth factor receptor 4 (FGFR4) selective inhibitor - Blueprint Medicines; Highly selective kinase drugs for specific genomically-defined cancer patients - Blueprint Medicines; Kinase inhibitors - Blueprint Medicines; KIT D816V selective inhibitor - Blueprint Medicines; NTRK inhibitors; Phosphotransferase inhibitors - Blueprint Medicines; PRKACA inhibitors - Blueprint Medicines; Protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions inhibitors; RET fusion inhibitors - Blueprint Medicines; RET inhibitors - Blueprint Medicines; TrkA inhibitors; Type 4 fibroblast growth factor receptor (FGFR4) antagonists - Blueprint Medicines

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Blueprint Medicines
  • Class Small molecules
  • Mechanism of Action Advanced glycosylation end product modulators; Fusion oncogene protein inhibitors; Phosphotransferase inhibitors; Protein kinase inhibitors; Protein kinase modulators; Proto oncogene protein c-kit inhibitors; Receptor protein-tyrosine kinase antagonists; TrkA receptor antagonists; Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Gastrointestinal stromal tumours; Hepatocellular carcinoma; Mastocytosis
  • Research Inborn genetic disorders

Most Recent Events

  • 27 Jan 2017 Blueprint Medicines Corporation plans a first-in-human phase I trial for Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease), Thyroid cancer and Solid tumours (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in USA (PO) (NCT03037385)
  • 17 Mar 2016 Interim pharmacodynamics data from preclinical studies in Cancer released by Blueprint Medicines
  • 15 Mar 2016 Blueprint Medicines and Roche enter into a worldwide collaboration and exclusive license agreement for the discovery, development and commercialization of up to five small molecule therapeutics targeting kinases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top